S Jeson Sangaralingham, MS, PhD

  • 650 Citations
  • 15 Scopus h-Index
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where S Jeson Sangaralingham is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 5 Similar Profiles
C-Type Natriuretic Peptide Medicine & Life Sciences
Natriuretic Peptides Medicine & Life Sciences
Heart Failure Medicine & Life Sciences
Kidney Medicine & Life Sciences
Brain Natriuretic Peptide Medicine & Life Sciences
Atrial Natriuretic Factor Medicine & Life Sciences
Fibrosis Medicine & Life Sciences
Guanylate Cyclase-Coupled Receptors Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1999 2019

  • 650 Citations
  • 15 Scopus h-Index
  • 34 Article
  • 1 Editorial
  • 1 Review article
2 Citations (Scopus)
C-Type Natriuretic Peptide
Cyclic GMP


Chen, Y., Harty, G. J., Zheng, Y., Iyer, S. R., Sugihara, S., Sangaralingham, S. J., Ichiki, T., Grande, J. P., Lee, H. C., Wang, X. & Burnett, J. C. J., May 10 2019, In : Circulation research. 124, 10, p. 1462-1472 11 p.

Research output: Contribution to journalArticle

Open Access
Acute Kidney Injury
C-Type Natriuretic Peptide
Protective Agents
2 Citations (Scopus)

Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide

Meems, L. M. G., Andersen, I. A., Pan, S., Harty, G., Chen, Y., Zheng, Y., Harders, G. E., Ichiki, T., Heublein, D. M., Iyer, S. R., Sangaralingham, S. J., Mc Cormick, D. J. & Burnett, J. C. J., Apr 1 2019, In : Hypertension (Dallas, Tex. : 1979). 73, 4, p. 900-909 10 p.

Research output: Contribution to journalArticle

Cardiovascular Diseases
8 Citations (Scopus)

Adoption of sacubitril/valsartan for the management of patients with heart failure

Sangaralingham, L. R., Sangaralingham, S. J., Shah, N. D., Yao, X. & Dunlay, S. M., Feb 1 2018, In : Circulation: Heart Failure. 11, 2, e004302.

Research output: Contribution to journalArticle

Heart Failure
United States Food and Drug Administration
Drug Approval
Drug Costs
1 Citation (Scopus)

A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure

Kawakami, R., Lee, C. Y. W., Scott, C., Bailey, K. R., Schirger, J. A., Chen, H. H., Benike, S. L., Cannone, V., Martin, F. L., Sangaralingham, S. J., Ichiki, T. & Burnett, J. C. J., Jan 1 2018, (Accepted/In press) In : Clinical Pharmacology and Therapeutics.

Research output: Contribution to journalArticle

Cyclic GMP
Heart Failure
Natriuretic Peptides
C-Type Natriuretic Peptide